SCPH Stock Price, Scpharmaceuticals Inc Quote, Chart

Market Summary

USD4.74-0.08

Market Closed

-1.66%

SCPH Stock Price

View Fullscreen

SCPH RSI Chart

SCPH Valuation

Market Cap

170.9M

Price/Earnings (Trailing)

-2.96

Price/Sales (Trailing)

9.69

Price/Free Cashflow

-2.83

SCPH Price/Sales (Trailing)

SCPH Profitability

Operating Margin

71.69%

Return on Equity

-234.91%

Return on Assets

-73.56%

Free Cashflow Yield

-35.37%

SCPH Fundamentals

SCPH Revenue

Revenue (TTM)

17.6M

Rev. Growth (Qtr)

0.1%

SCPH Earnings

Earnings (TTM)

-57.7M

Earnings Growth (Yr)

-25.85%

Earnings Growth (Qtr)

-2.14%

Breaking Down SCPH Revenue

Last 7 days

5.8%

Last 30 days

7.2%

Last 90 days

-17.4%

Trailing 12 Months

-56.5%

How does SCPH drawdown profile look like?

SCPH Financial Health

Current Ratio

6.21

Debt/Equity

1.6

Debt/Cashflow

-1.53

SCPH Investor Care

Shares Dilution (1Y)

0.80%

Diluted EPS (TTM)

-1.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	17.6M	0	0	0
2023	0	0	0	13.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Scpharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 18, 2024	nokes rachael	acquired	-	-	41,840	cfo and treasurer
Jan 18, 2024	tucker john h	acquired	-	-	113,560	president and ceo
Jan 02, 2024	nokes rachael	sold (taxes)	-6,562	6.39	-1,027	cfo and treasurer
Jan 02, 2024	tucker john h	sold (taxes)	-31,579	6.39	-4,942	president and ceo
Jan 19, 2023	nokes rachael	acquired	71,838	6.14	11,700	see remarks
Jan 19, 2023	tucker john h	acquired	409,323	6.14	66,665	president and ceo
Nov 25, 2022	orbimed advisors llc	bought	4,002,500	5.25	762,380	-
Oct 10, 2022	5am partners iv, llc	sold	-1,866,730	4.09	-456,413	-
Oct 10, 2022	5am partners iv, llc	sold	-77,779	4.09	-19,017	-
Oct 10, 2022	5am partners iv, llc	sold	-355,977	4.09	-87,036	-

Which funds bought or sold SCPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	48.47	28,254	177,994	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-15,228	14,573	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-79,629	-	-%
May 15, 2024	DEUTSCHE BANK AG\	added	806	62,034	71,947	-%
May 15, 2024	SHERBROOKE PARK ADVISERS LLC	new	-	72,398	72,398	0.01%
May 15, 2024	BARCLAYS PLC	reduced	-48.84	-147,000	102,000	-%
May 15, 2024	Laurion Capital Management LP	sold off	-100	-262,544	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-13.19	-62,279	141,961	-%
May 15, 2024	J. Goldman & Co LP	reduced	-20.36	-3,191,290	5,615,600	0.18%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-47.02	-1,288,390	949,202	-%

Are Funds Buying or Selling SCPH?

Are funds buying SCPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SCPH

No. of Funds

Unveiling Scpharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 29, 2024	lytton laurence w	5.1%	1,825,234	SC 13G
Apr 05, 2024	blackrock inc.	4.99%	1,801,610	SC 13G/A
Feb 14, 2024	armistice capital, llc	0%	0	SC 13G/A
Feb 14, 2024	5am ventures iv, l.p.	2.7%	980,963	SC 13G/A
Feb 12, 2024	rubric capital management lp	9.76%	3,500,000	SC 13G
Feb 07, 2024	hirschman orin	8.7%	3,106,795	SC 13G/A
Feb 02, 2024	cowen financial products llc	-	0	SC 13G/A
Feb 02, 2024	blackrock inc.	5.2%	1,863,439	SC 13G
Jan 12, 2024	millennium management llc	1.0%	356,873	SC 13G/A
Mar 13, 2023	millennium management llc	5.1%	1,722,839	SC 13G

Recent SEC filings of Scpharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
Apr 29, 2024	SC 13G	Major Ownership Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 02, 2024	4	Insider Trading
Mar 22, 2024	EFFECT	EFFECT

Peers (Alternatives to Scpharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Scpharmaceuticals Inc News

Latest updates

Scpharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Revenue	0.1%	6,102	6,096	3,796	1,638	2,063
Cost Of Revenue	0.7%	1,785	1,773	1,079	354	605
Operating Expenses	2.8%	21,958	21,353	18,635	15,384	13,617
S&GA Expenses	7.4%	17,447	16,242	14,135	12,096	10,896
R&D Expenses	-18.3%	2,726	3,338	3,421	2,934	2,116
Interest Expenses	0.4%	2,101	2,092	2,060	2,010	1,961
Net Income	-2.1%	-14,108	-13,812	-15,634	-14,154	-11,210
Net Income Margin	18.8%	-3.27*	-4.03*	-	-	-
Free Cashflow	-17.1%	-17,738	-15,151	-13,451	-14,141	-16,494

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.0%	78.00	94.00	106	114	127	124	48.00	59.00	69.00	79.00	88.00	94.00	100	109	117	124	80.00	77.00	87.00	83.00	88.00
Current Assets	-17.7%	77.00	93.00	104	114	127	123	47.00	58.00	68.00	78.00	86.00	92.00	99.00	108	116	123	79.00	76.00	85.00	82.00	86.00
Cash Equivalents	24.8%	58.00	47.00	35.00	71.00	75.00	71.00	41.00	41.00	52.00	74.00	80.00	75.00	76.00	72.00	44.00	79.00	76.00	73.00	84.00	80.00	84.00
Inventory	8.3%	10.00	9.00	7.00	6.00	4.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-10.3%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-5.9%	54.00	57.00	57.00	51.00	52.00	52.00	17.00	19.00	20.00	23.00	24.00	25.00	25.00	27.00	27.00	26.00	25.00	26.00	29.00	20.00	17.00
Current Liabilities	-6.2%	12.00	13.00	11.00	7.00	8.00	7.00	17.00	16.00	14.00	15.00	14.00	12.00	10.00	9.00	7.00	6.00	5.00	5.00	8.00	14.00	10.00
Long Term Debt	1.5%	39.00	39.00	38.00	38.00	37.00	37.00	-	2.00	5.00	7.00	10.00	12.00	15.00	17.00	19.00	19.00	19.00	19.00	19.00	5.00	6.00
LT Debt, Current	-	-	-	-	-	-	-	10.00	10.00	10.00	10.00	10.00	7.00	5.00	2.00	-	-	-	-	-	5.00	4.00
LT Debt, Non Current	-100.0%	-	39.00	38.00	38.00	37.00	37.00	-	2.00	5.00	7.00	10.00	12.00	15.00	17.00	19.00	19.00	19.00	19.00	19.00	5.00	6.00
Shareholder's Equity	-34.0%	25.00	37.00	49.00	63.00	76.00	72.00	31.00	40.00	49.00	56.00	63.00	69.00	76.00	82.00	90.00	98.00	55.00	51.00	58.00	63.00	70.00
Retained Earnings	-5.0%	-295	-281	-267	-251	-237	-226	-217	-207	-197	-189	-182	-175	-168	-161	-153	-144	-136	-129	-118	-112	-105
Additional Paid-In Capital	0.5%	320	319	317	315	314	299	248	248	247	246	245	245	244	244	244	243	192	181	177	176	176
Shares Outstanding	0.2%	36.00	36.00	36.00	36.00	36.00	34.00	27.00	27.00	27.00	27.00	27.00	27.00	27.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	274	-	-	-	76.00	-	-	-	94.00	-	-	-	113	-	-	-	27.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-17.1%	-17,701	-15,114	-13,451	-14,141	-16,494	-11,837	-8,196	-7,175	-7,369	-7,098	-5,167	-6,271	-8,615	-9,180	-4,808	-5,962	-7,743	-14,835	-5,578	-3,911	-6,118
Share Based Compensation	1.7%	1,440	1,416	1,281	1,179	980	737	785	680	636	637	619	589	521	127	744	621	508	435	333	326	355
Cashflow From Investing	10.8%	29,319	26,463	-22,925	9,427	7,000	-42,992	10,784	-861	-12,790	4,501	9,521	5,403	12,705	36,701	-29,692	-	-	-	-	-	-
Cashflow From Financing	-96.8%	15.00	467	68.00	611	13,704	84,601	-2,477	-2,416	-2,479	-2,458	-	-	-72.00	20.00	-82.00	49,952	10,458	3,897	9,673	-	18.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SCPH Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product revenues, net	$ 6,102	$ 2,063
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Operating expenses:
Cost of product revenues	$ 1,785	$ 605
Research and development	2,726	2,116
Selling, general and administrative	17,447	10,896
Total operating expenses	21,958	13,617
Loss from operations	(15,856)	(11,554)
Other income	2,972	990
Interest income	877	1,315
Interest expense	(2,101)	(1,961)
Net loss	$ (14,108)	$ (11,210)
Net loss per share - basic	$ (0.36)	$ (0.3)
Net loss per share - diluted	$ (0.36)	$ (0.3)
Weighted average common shares outstanding - basic	38,952,131	37,800,960
Weighted average common shares outstanding - diluted	38,952,131	37,800,960
Other comprehensive loss:
Unrealized (loss) gain on short-term investments	$ 1	$ (24)
Comprehensive loss	$ (14,107)	$ (11,234)

SCPH Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 58,447	$ 46,814
Short-term investments		29,199
Accounts receivable, net	5,772	4,489
Inventory, net	9,572	8,840
Prepaid expenses	2,198	2,436
Deposits and other current assets	536	1,160
Total current assets	76,525	92,938
Property and equipment, net	52	58
Right-of-use lease assets - operating, net	1,355	1,401
Deposits and other assets	522	82
Total assets	78,454	94,479
Current liabilities
Accounts payable	2,706	4,001
Accrued expenses	9,206	8,901
Lease obligation - operating, short-term	184	176
Other current liabilities	222	56
Total current liabilities	12,318	13,134
Term loan, long-term	39,385	38,811
Derivative liability	733	3,857
Lease obligation - operating, long-term	1,233	1,282
Other liabilities	219	177
Total liabilities	53,888	57,261
Commitments and contingencies (Note 12)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding
Common stock, $0.0001 par value; 150,000,000 shares authorized as of March 31, 2024; 35,968,510 and 36,054,409 shares issued and outstanding as of December 31, 2023 and March 31, 2024, respectively	4	4
Additional paid-in capital	320,016	318,561
Accumulated deficit	(295,454)	(281,346)
Accumulated other comprehensive income		(1)
Total stockholders’ equity	24,566	37,218
Total liabilities and stockholders’ equity	$ 78,454	$ 94,479

About Scpharmaceuticals Inc

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

CEO	Mr. John H. Tucker
WEBSITE	scpharmaceuticals.com
INDUSTRY	Biotechnology
EMPLOYEES	96

Scpharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Scpharmaceuticals Inc? What does SCPH stand for in stocks?

SCPH is the stock ticker symbol of Scpharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Scpharmaceuticals Inc (SCPH)?

As of Fri May 17 2024, market cap of Scpharmaceuticals Inc is 170.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SCPH stock?

You can check SCPH's fair value in chart for subscribers.

What is the fair value of SCPH stock?

You can check SCPH's fair value in chart for subscribers. The fair value of Scpharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Scpharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SCPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Scpharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SCPH is over valued or under valued. Whether Scpharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Scpharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SCPH.

What is Scpharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SCPH's PE ratio (Price to Earnings) is -2.96 and Price to Sales (PS) ratio is 9.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SCPH PE ratio will change depending on the future growth rate expectations of investors.